The biosimilar market will soon be booming as over $80 billion worth of drugs go off patent in the next 7 years, said Amit Munshi, CEO of Epirus Biopharmaceuticals. Munshi added that half of that patent cliff will take place outside the U.S. which is why Epirus is focusing on the emerging markets. Epirus lead asset is infliximab, which is a generic version of the Johnson & Johnson/Merck arthritis drug Remicade. In the past week Epirus received an approval of BOW015, the first infliximab biosimilar approved for rheumatoid arthritis in India. Epirus also announced a partnership with Livzon Mabpharm to develop up to 5 biosimilars for Asian markets.